Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Rhea-AI Summary
Revolution Medicines (Nasdaq: RVMD) announced that Mark A. Goldsmith, M.D., Ph.D., CEO and chairman, will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 9:30 a.m. ET.
According to the company, the session will be webcast live and a replay will be available on the company's investor website for at least 14 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction – RVMD
In the Feb 5 session, RVMD declined 0.37%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 29 | Clinical trial start | Positive | +0.9% | First patient dosed in RMC-5127-001 first-in-human trial. |
| Jan 08 | Regulatory designation | Positive | +4.6% | FDA Breakthrough Therapy Designation for zoldonrasib in KRAS G12D NSCLC. |
| Jan 05 | Conference participation | Positive | +1.9% | J.P. Morgan Healthcare Conference presentation and webcast availability. |
| Dec 18 | Phase 3 trial progress | Positive | -1.0% | First patient randomized in Phase 3 RASolute 304 daraxonrasib trial. |
| Nov 05 | Earnings and pipeline | Positive | +1.3% | Q3 2025 results with RASolute program updates and strong cash balance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, especially clinical and regulatory milestones, has typically seen RVMD trade higher, with only one negative reaction among the last five items.
Over the past few months, RVMD has reported multiple clinical and regulatory milestones, including first patient dosing in RMC-5127-001 on Jan 29, 2026, FDA Breakthrough Therapy Designation for zoldonrasib on Jan 8, 2026, and Phase 3 RASolute 304 randomization on Dec 18, 2025. Q3 2025 results on Nov 5, 2025 highlighted cash and marketable securities of $1.93B. Prior conference participation, such as the 44th J.P. Morgan event on Jan 12, 2026, also saw a positive price reaction, similar in nature to today’s Guggenheim conference announcement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in a fireside chat as part of the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 9:30 a.m. ET.
To listen to a live webcast of this event, or access an archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com
